Incyte Company Insiders
| INCY Stock | USD 51.74 0.09 0.17% |
Incyte's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Incyte suggests that vertually all insiders are panicking. Incyte employs about 2.5 K people. The company is managed by 32 executives with a total tenure of roughly 227 years, averaging almost 7.0 years of service per executive, having 78.88 employees per reported executive.
| Julian Baker Chairman Independent Vice Chairman of the Board |
| Herve Hoppenot Chairman Chairman, CEO and President and Member of Non-Management Stock Option Committee |
Incyte's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-01-02 | Vijay K Iyengar | Disposed 657 @ 65 | View | ||
| 2023-12-12 | Thomas Tray | Disposed 210 @ 57.36 | View |
Monitoring Incyte's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Incyte |
Incyte's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Incyte's future performance. Based on our forecasts, it is anticipated that Incyte will maintain a workforce of slightly above 2520 employees by May 2024.Incyte's latest congressional trading
Congressional trading in companies like Incyte, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Incyte by those in governmental positions are based on the same information available to the general public.
| 2023-03-06 | Representative Daniel Goldman | Acquired Under $15K | Verify | ||
| 2020-12-22 | Representative Gilbert Cisneros | Disposed Under $15K | Verify | ||
| 2018-11-12 | Senator Shelley Moore Capito | Acquired Under $15K | Verify |
Incyte Management Team Effectiveness
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.Net Income Applicable To Common Shares is likely to rise to about 411.3 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 130.7 M in 2024.
Incyte Workforce Comparison
Incyte is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 3,084. Incyte totals roughly 2,524 in number of employees claiming about 82% of equities under Health Care industry.
Incyte Profit Margins
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.39 | 0.931 |
|
|
Incyte Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Incyte insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.3846 | 18 | 13 | 363,697 | 13,969 |
| 2023-12-01 | 3.0 | 6 | 2 | 57,196 | 1,277 |
| 2023-09-01 | 2.1818 | 24 | 11 | 384,297 | 121,892 |
| 2023-06-01 | 23.0 | 23 | 1 | 486,704 | 488.00 |
| 2023-03-01 | 1.5172 | 44 | 29 | 640,732 | 174,322 |
| 2022-12-01 | 1.375 | 11 | 8 | 31,800 | 33,080 |
| 2022-09-01 | 2.5833 | 31 | 12 | 488,400 | 51,293 |
| 2022-06-01 | 3.375 | 27 | 8 | 154,531 | 97,862 |
| 2022-03-01 | 1.2115 | 63 | 52 | 2,997,451 | 163,447 |
| 2021-12-01 | 8.75 | 35 | 4 | 1,654,880 | 40,922 |
| 2021-09-01 | 1.3043 | 30 | 23 | 330,904 | 44,409 |
| 2021-06-01 | 1.8571 | 26 | 14 | 117,314 | 151,855 |
| 2021-03-01 | 1.5 | 36 | 24 | 328,638 | 86,177 |
| 2020-12-01 | 1.6 | 24 | 15 | 43,669 | 50,513 |
| 2020-09-01 | 0.7833 | 47 | 60 | 453,228 | 373,078 |
| 2020-06-01 | 1.1778 | 53 | 45 | 513,941 | 675,777 |
| 2020-03-01 | 2.0 | 42 | 21 | 416,657 | 98,078 |
| 2019-12-01 | 0.8261 | 38 | 46 | 220,080 | 320,762 |
| 2019-09-01 | 0.8974 | 35 | 39 | 420,487 | 240,307 |
| 2019-06-01 | 2.0 | 30 | 15 | 558,215 | 2,336,252 |
| 2019-03-01 | 1.5333 | 46 | 30 | 748,814 | 279,133 |
| 2018-12-01 | 3.0 | 15 | 5 | 133,508 | 41,000 |
| 2018-09-01 | 1.0417 | 25 | 24 | 312,576 | 69,822 |
| 2018-06-01 | 4.1429 | 29 | 7 | 429,184 | 213,900 |
| 2018-03-01 | 2.0 | 28 | 14 | 316,713 | 72,451 |
| 2017-12-01 | 2.0 | 8 | 4 | 34,924 | 37,031 |
| 2017-09-01 | 1.3421 | 51 | 38 | 334,454 | 165,514 |
| 2017-06-01 | 1.0244 | 42 | 41 | 333,705 | 305,463 |
| 2017-03-01 | 2.2 | 44 | 20 | 11,154,265 | 12,024,815 |
| 2016-12-01 | 1.1818 | 13 | 11 | 57,166 | 114,541 |
| 2016-09-01 | 6.6 | 33 | 5 | 357,642 | 170,000 |
| 2016-06-01 | 4.2 | 21 | 5 | 238,737 | 50,311 |
| 2016-03-01 | 11.3333 | 136 | 12 | 5,264,802 | 117,540 |
| 2015-12-01 | 1.0 | 25 | 25 | 250,589 | 523,842 |
| 2015-09-01 | 0.963 | 26 | 27 | 4,744,907 | 1,127,784 |
| 2015-06-01 | 0.5679 | 46 | 81 | 681,153 | 1,064,321 |
| 2015-03-01 | 1.0114 | 89 | 88 | 981,102 | 1,253,112 |
| 2014-12-01 | 0.625 | 25 | 40 | 363,661 | 773,825 |
| 2014-09-01 | 0.6667 | 12 | 18 | 57,333 | 114,666 |
| 2014-06-01 | 0.9565 | 22 | 23 | 232,777 | 242,612 |
| 2014-03-01 | 1.1667 | 42 | 36 | 1,394,115 | 1,487,263 |
| 2013-12-01 | 2.1 | 21 | 10 | 533,545,000 | 117,407,000 |
| 2013-09-01 | 0.5 | 5 | 10 | 161,244 | 375,522 |
| 2013-06-01 | 1.7143 | 12 | 7 | 220,000 | 175,699 |
| 2013-03-01 | 1.5 | 15 | 10 | 705,006 | 360,163 |
| 2012-12-01 | 3.0 | 3 | 1 | 345,000 | 50,000 |
| 2012-09-01 | 0.4444 | 4 | 9 | 92,366 | 164,732 |
| 2012-06-01 | 1.0 | 18 | 18 | 312,389 | 410,754 |
| 2012-03-01 | 1.8667 | 28 | 15 | 1,062,864 | 135,000 |
| 2011-06-01 | 0.1327 | 13 | 98 | 371,664 | 567,007 |
| 2011-03-01 | 0.5625 | 18 | 32 | 808,367 | 527,843 |
| 2010-06-01 | 7.0 | 21 | 3 | 342,251 | 195,834 |
| 2010-03-01 | 5.5 | 11 | 2 | 394,000 | 40,000 |
| 2009-09-01 | 0.7273 | 8 | 11 | 162,000,000 | 97,717,353 |
| 2009-03-01 | 6.4545 | 71 | 11 | 47,561,303 | 343,750 |
| 2007-12-01 | 51.3333 | 154 | 3 | 3,569,164 | 48,654 |
| 2007-03-01 | 3.0 | 6 | 2 | 240,000 | 39,206 |
| 2006-06-01 | 5.0 | 10 | 2 | 9,478,937 | 530,235 |
| 2005-06-01 | 0.75 | 6 | 8 | 120,000 | 5,103,500 |
| 2004-03-01 | 0.2692 | 7 | 26 | 122,000 | 0.00 |
Incyte Notable Stakeholders
An Incyte stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Incyte often face trade-offs trying to please all of them. Incyte's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Incyte's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Julian Baker | Independent Vice Chairman of the Board | Profile | |
| Herve Hoppenot | Chairman, CEO and President and Member of Non-Management Stock Option Committee | Profile | |
| Steven Stein | Senior Vice President and Chief Medical Officer | Profile | |
| Eric Siegel | Executive Vice President General Counsel | Profile | |
| Vijay Iyengar | Executive Vice President Global Strategy and Corporate Development` | Profile | |
| Richard Levy | Executive Vice President Chief Drug Development and Medical Officer | Profile | |
| Maria Pasquale | Executive Vice President General Counsel | Profile | |
| Christiana Stamoulis | CFO, Executive Vice President | Profile | |
| David Gryska | CFO, Executive Vice President | Profile | |
| Wenqing Yao | Executive Vice President - Discovery Medicinal and Process Chemistry | Profile | |
| Barry Flannelly | Executive Vice President - Business Development and Strategic Planning | Profile | |
| Dashyant Dhanak | Executive Vice President Chief Scientific Officer | Profile | |
| Christiana MBA | Executive CFO | Profile | |
| Reid Huber | Chief Scientific Officer and Executive VP | Profile | |
| JeanJacques Bienaime | Independent Director | Profile | |
| Paul Brooke | Independent Director | Profile | |
| Paul Friedman | Director | Profile | |
| Jacqualyn Fouse | Director | Profile | |
| Paul Clancy | Director | Profile | |
| Wendy Dixon | Independent Director | Profile | |
| Paul Trower | Principal Accounting Officer and VP of Fin. | Profile | |
| Michael Booth | VP - Investor Relations | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Christine Chiou | Head Relations | Profile | |
| PharmD MBA | Executive America | Profile | |
| Steven MD | Executive Officer | Profile | |
| Sheila Denton | Executive Counsel | Profile | |
| Paula Swain | Executive Resources | Profile | |
| Michael Morrissey | Executive Operations | Profile | |
| Maria JD | Gen VP | Profile | |
| MBA MBA | Ex America | Profile |
About Incyte Management Performance
The success or failure of an entity such as Incyte often depends on how effective the management is. Incyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Incyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Incyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.1 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.12 | 0.19 |
The data published in Incyte's official financial statements usually reflect Incyte's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Incyte. For example, before you start analyzing numbers published by Incyte accountants, it's critical to develop an understanding of what Incyte's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Incyte's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Please utilize our Beneish M Score to check the likelihood of Incyte's management manipulating its earnings.
Incyte Workforce Analysis
Traditionally, organizations such as Incyte use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Incyte within its industry.Incyte Manpower Efficiency
Return on Incyte Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 115.5M | |
| Net Income Per Employee | 236.8K | |
| Net Income Per Executive | 18.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 106.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.324 | Earnings Share 2.65 | Revenue Per Share 16.526 | Quarterly Revenue Growth 0.093 | Return On Assets 0.0646 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.